Follicular lymphoma grade I
ICD-10 C82.0 is a billable code used to indicate a diagnosis of follicular lymphoma grade i.
Follicular lymphoma grade I is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. It is classified as a low-grade lymphoma, meaning it typically has a slower progression compared to higher-grade lymphomas. Patients may present with painless lymphadenopathy, often in the cervical, axillary, or inguinal regions. The disease can be indolent, with many patients remaining asymptomatic for extended periods. However, some may experience B-symptoms, which include fever, night sweats, and unexplained weight loss. Diagnosis is confirmed through lymph node biopsy, which reveals the characteristic follicular architecture and the presence of neoplastic follicle center cells. Staging is crucial for treatment planning and is typically performed using the Ann Arbor system, which assesses the extent of lymph node involvement and any extranodal disease. Treatment options may include watchful waiting for asymptomatic patients, chemotherapy, immunotherapy, or a combination of these modalities, depending on the disease stage and patient health status.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis and management of newly diagnosed follicular lymphoma, treatment response assessments, and management of relapsed disease.
Ensure accurate documentation of histological findings and treatment regimens to support coding.
Comprehensive biopsy reports detailing histological findings and immunophenotyping.
Evaluation of lymph node biopsies for lymphoma diagnosis and grading.
Pathology reports must clearly indicate the grade and subtype of lymphoma for accurate coding.
Used during treatment of follicular lymphoma grade I.
Document the specific chemotherapy regimen and patient response.
Oncology specialists must ensure accurate coding of chemotherapy sessions.
Follicular lymphoma grade I generally has a favorable prognosis, with many patients living for years without significant symptoms. However, the disease can transform into a higher-grade lymphoma, which may require more aggressive treatment.
